HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Nov 2018 07:00 AM
RNS
Phase III FALUCA Trial Results for Fruquintinib
31 Oct 2018 07:00 AM
RNS
Total Voting Rights
22 Oct 2018 10:05 AM
RNS
Grant of Share Options under Share Option Scheme
18 Oct 2018 07:00 AM
RNS
Chi-Med Initiates a Ph I Trial of HMPL-523 for AML
05 Oct 2018 07:00 AM
RNS
Appointment of HSBC Bank plc as Broker in London
05 Sep 2018 07:00 AM
RNS
Fruquintinib Approved for CRC in China
31 Aug 2018 07:00 AM
RNS
Total Voting Rights
07 Aug 2018 10:00 AM
RNS
Grant of Share Options under Share Option Scheme
27 Jul 2018 07:00 AM
RNS
2018 Interim Results and Clinical Programs Update
23 Jul 2018 07:00 AM
RNS
Start of Sulfatinib US Phase Ib/II PoC trial
29 Jun 2018 07:02 AM
RNS
Total Voting Rights
29 Jun 2018 07:01 AM
RNS
Blocklisting Six Monthly Return
29 Jun 2018 07:00 AM
RNS
Chi-Med to Announce Half-Year Financial Results
07 Jun 2018 10:00 AM
RNS
Grant of Share Options under Share Option Scheme
04 Jun 2018 09:41 AM
RNS
Further Fruquintinib FRESCO Trial Data - ASCO 2018
31 May 2018 07:00 AM
RNS
Total Voting Rights
30 Apr 2018 07:00 AM
RNS
Total Voting Rights
27 Apr 2018 01:52 PM
RNS
Results of Annual General Meeting
23 Apr 2018 01:10 PM
RNS
Grant of Share Options under Share Option Scheme
23 Apr 2018 01:05 PM
RNS
Block Admission
29 Mar 2018 07:00 AM
RNS
Total Voting Rights
28 Mar 2018 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
26 Mar 2018 07:00 AM
RNS
Annual Report & Notice of Annual General Meeting
21 Mar 2018 09:25 AM
RNS
Director's Share Dealing
20 Mar 2018 09:15 AM
RNS
Grant of Share Options under Share Option Scheme
19 Mar 2018 07:10 AM
RNS
Director's Share Dealing
12 Mar 2018 11:22 AM
RNS
Publication of Form 20-F
12 Mar 2018 07:02 AM
RNS
Final Results and Key Clinical Programs Update
06 Mar 2018 07:00 AM
RNS
Phase Ib/II Trial of Epitinib in Glioblastoma
13 Feb 2018 07:01 AM
RNS
Enrolment completed Ph III FALUCA Fruquintinib
05 Feb 2018 07:00 AM
RNS
Chi-Med to Announce 2017 Final Results
29 Dec 2017 07:00 AM
RNS
Block listing Interim Review
29 Dec 2017 07:00 AM
RNS
Total Voting Rights
15 Dec 2017 07:00 AM
RNS
Chi-Med Initiates Fruquintinib US Clinical Trials
01 Nov 2017 09:45 AM
RNS
Notification of Major Holdings
01 Nov 2017 09:45 AM
RNS
NOTIFICATION OF MAJOR HOLDINGS
31 Oct 2017 07:00 AM
RNS
FRUTIGA, a Phase III trial of Fruquintinib
30 Oct 2017 03:30 PM
RNS
Closing of U.S. Public Offering of ADSs
27 Oct 2017 12:10 PM
RNS
Chi-Med Announces Over-allotment Option
26 Oct 2017 07:00 AM
RNS
Chi-Med Announces Pricing Raising US$262 million
25 Oct 2017 07:00 AM
RNS
Chi-Med Announces Proposed Offering of ADSs
19 Oct 2017 09:20 AM
RNS
Notification of Major Interest in Shares
17 Oct 2017 07:00 AM
RNS
Savolitinib Shows Encouraging Clinical Activity
16 Oct 2017 07:00 AM
RNS
Chi-Med Reports Preliminary Phase II data
12 Oct 2017 07:30 AM
RNS
Appointment of Director
29 Sep 2017 07:04 AM
RNS
Savolitinib and Fruquintinib presentations at WCLC
29 Sep 2017 07:00 AM
RNS
Oral Presentations at CSCO Annual Meeting
29 Sep 2017 07:00 AM
RNS
Total Voting Rights
31 Aug 2017 10:15 AM
RNS
Director's Share Dealing
29 Aug 2017 07:00 AM
RNS
Start of HMPL 689 Phase I Trial in China

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings